Related Experiment Video

Updated: May 12, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Toll-like receptor signalling and their therapeutic targeting in colorectal cancer

Shirin Moossavi1, Nima Rezaei

  • 1Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran. shirin.moossavi@gmail.com

International Immunopharmacology
|April 23, 2013
PubMed

Insights

Toll-like receptors (TLRs) are crucial for gut health. Their dysregulation is linked to colorectal cancer, suggesting TLRs as potential therapeutic targets for this disease.

Area of Science:

  • Immunology
  • Gastroenterology
  • Oncology

Background:

  • Intestinal homeostasis relies on host/microbiota interactions mediated by pattern recognition receptors.
  • Toll-like receptors (TLRs) are key membrane receptors detecting conserved microbial structures essential for intestinal balance.

Purpose of the Study:

  • To review the evidence linking TLRs to colorectal cancer pathogenesis.
  • To explore mechanisms affecting TLR signaling in colorectal cancer.
  • To discuss therapeutic targeting of TLRs for colorectal cancer treatment.

Main Methods:

  • Literature review of studies on TLRs, microbiota, and colorectal cancer.
  • Analysis of potential molecular mechanisms.
  • Evaluation of therapeutic strategies targeting TLRs.

Main Results:

  • Emerging evidence implicates microbiota and TLRs in colorectal cancer development.
  • Dysregulated TLR signaling can lead to immune dysregulation contributing to colorectal cancer.
  • Specific TLR pathways are being investigated for their role in disease progression.

Conclusions:

  • TLRs play a significant role in the pathogenesis of colorectal cancer.
  • Understanding TLR signaling mechanisms is crucial for developing novel therapies.
  • Targeting TLRs offers a promising therapeutic avenue for colorectal cancer treatment.

More Related Videos

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...